A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium

✍ Scribed by Christopher J. Sweeney; Stephen D. Williams; David E. Finch; Richard Bihrle; Richard S. Foster; Mary Collins; Susan Fox; Bruce J. Roth

• Publisher: John Wiley and Sons
• Year: 1999
• Tongue: English
• Weight: 62 KB
• Volume: 86
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19990801)86:3<514::aid-cncr21>3.0.co;2-9

✦ Synopsis

BACKGROUND.

Cisplatin-based combination chemotherapy for patients with advanced transitional cell carcinoma (TCC) of the urothelium has limitations, and new therapies need to be evaluated.

METHODS. Ifosfamide 1.0 gm/m 2 on Days 1-4 and paclitaxel 135 mg/m 2 by 24-hour infusion on Day 4 were administered to 26 patients with locally unresectable or metastatic TCC. Cycles were repeated every 21 days for a maximum of 6 cycles; dose escalation was dependent on whether Grade 3 or 4 toxicities occurred.